Financial Performance - For the three months ended March 31, 2023, the company recorded revenue of approximately RMB 142,544,000, a decrease of about RMB 50,823,000 compared to the same period last year[14]. - The profit attributable to shareholders for the same period was RMB 52,388,000, an increase of 56% from RMB 33,615,000 in the previous year[14]. - The basic earnings per share for the three months ended March 31, 2023, was RMB 0.0935, compared to RMB 0.0660 for the same period in 2022[30]. - Revenue for the first quarter of 2023 was RMB 142,544,000, a decrease of 26.3% compared to RMB 193,367,000 in the same period of 2022[61]. - Gross profit for the first quarter of 2023 was RMB 100,789,000, down 37.8% from RMB 161,864,000 year-over-year[61]. - Operating profit increased to RMB 67,224,000, compared to RMB 39,863,000 in the first quarter of 2022, representing a growth of 68.8%[61]. - Profit attributable to shareholders for the first quarter of 2023 was RMB 52,388,000, an increase of 55.8% from RMB 33,615,000 in the same quarter of 2022[61]. - Basic earnings per share for the first quarter of 2023 were 9.35 cents, compared to 6 cents in the first quarter of 2022, reflecting a 55.8% increase[61]. - Other income for the first quarter of 2023 was RMB 45,831,000, significantly up from RMB 5,701,000 in the same period last year[61]. Cost Management - The distribution and selling costs as a percentage of revenue decreased to 44.2% from 46.8% in the previous year, a reduction of 2.6%[15]. - Administrative expenses decreased from RMB 37,153,000 in the previous year to RMB 16,387,000 in the current year[15]. - Financial expenses decreased to RMB 26,000 from RMB 480,000 in the first quarter of 2022, indicating improved financial management[61]. Dividends - The company plans to distribute a special dividend of RMB 0.50 per share, totaling RMB 280,125,000, subject to shareholder approval[32]. - The board proposed a special dividend of RMB 0.50 per share, subject to shareholder approval at the upcoming extraordinary general meeting[34]. - The company declared a dividend of RMB 280,125,000 for the first quarter of 2023, compared to RMB 35,016,000 in the same period of 2022[61]. - The company did not recommend the payment of an interim dividend for the three months ended March 31, 2023[10]. Production and Operations - The company has officially commenced production in its small-volume injection workshop, increasing production capacity[37]. - The product catalog continues to expand, enhancing the company's R&D capabilities and market competitiveness[38]. - The company continues to operate in the manufacturing and distribution of traditional Chinese medicine and pharmaceutical products without any changes in business nature[62]. Financial Position - As of March 31, 2023, the company's cash and bank balances totaled RMB 978,742,000, up from RMB 834,176,000 in 2022[38]. - The unaudited net asset value of the group as of March 31, 2023, was approximately RMB 1,664,686,000, compared to RMB 1,487,364,000 in 2022[38]. - The capital debt ratio as of March 31, 2023, was 0.02%, a slight decrease from 0.03% on March 31, 2022[39]. - The company maintains a robust financial position, with no significant fluctuations in production and material costs reported[35]. Corporate Governance - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM listing rules[55]. - The chairman, Zhang Hong, is also the CEO, a situation the board believes does not affect accountability or independent decision-making[57]. - The effective corporate income tax rate for the company remains at 15% for the three months ended March 31, 2023, consistent with the previous year[8]. - There were no potential diluted shares during the reporting period, hence no diluted earnings per share were presented[9].

Financial Performance - For the three months ended March 31, 2023, the company reported revenue of RMB 142,544,000, a decrease of 26.3% compared to RMB 193,367,000 for the same period in 2022[5] - Gross profit for the same period was RMB 100,789,000, down 37.8% from RMB 161,864,000 year-over-year[5] - Operating profit increased to RMB 67,224,000, compared to RMB 39,863,000 in the previous year, reflecting a growth of 68.7%[5] - Profit attributable to shareholders was RMB 52,388,000, representing a 55.8% increase from RMB 33,615,000 in the same quarter of 2022[5] - Basic earnings per share rose to 9.35 cents, up from 6 cents year-over-year[5] - Other income significantly increased to RMB 45,831,000 from RMB 5,701,000, marking a growth of 705.5%[5] - As of March 31, 2023, the company reported a net profit of RMB 52,388,000 for the three-month period, an increase from RMB 33,615,000 for the same period in 2022, representing a growth of approximately 55.8%[25] - The gross margin for the three months ended March 31, 2023, was approximately 70.7%, a decrease of 13% compared to 83.7% for the same period in 2022[28] Dividends and Shareholder Returns - The company did not recommend the payment of an interim dividend for the three months ended March 31, 2023, consistent with the previous year[24] - The board of directors proposed a special dividend of RMB 0.50 per share (before tax), totaling RMB 280,125,000, which is significantly higher than the RMB 35,015,625 distributed in the previous fiscal year[47] - The company plans to hold a special general meeting on June 2, 2023, to approve the proposed special dividend[47] Taxation and Financial Position - The effective corporate income tax rate for the company remains at 15% for the period, unchanged from the previous year[22] - The company’s income tax expense for the three months ended March 31, 2023, was RMB 14,810,000, compared to RMB 5,768,000 for the same period in 2022, indicating an increase in tax obligations[45] - The company's cash and bank balances totaled RMB 978,742,000 as of March 31, 2023, up from RMB 834,176,000 as of March 31, 2022, indicating a year-over-year increase of approximately 17.3%[31] - The unaudited consolidated net asset value of the company was approximately RMB 1,664,686,000 as of March 31, 2023, compared to RMB 1,487,364,000 as of March 31, 2022, reflecting a growth of about 11.9%[31] - As of March 31, 2023, the company's debt-to-asset ratio was 0.02%, down from 0.03% on March 31, 2022[57] Operational Developments - The company operates primarily in the manufacturing and distribution of traditional Chinese medicine and pharmaceutical products within China[12] - The company has successfully passed the consistency evaluation for its injectable product and has entered the seventh batch of national collection, indicating progress in product development and commercialization[29] - The company has officially commenced production in its small-volume injection workshops, increasing production capacity[53] - The company's product portfolio continues to expand, enhancing its R&D capabilities and market competitiveness[54] - The company maintained a stable financial position during the reporting period, with no significant fluctuations in production and material costs reported[28] Compliance and Governance - The financial results are unaudited and have been reviewed by the company's audit committee[19] - The company has adopted relevant guidelines for directors conducting securities transactions, ensuring compliance with GEM listing rules[64] - The company has not purchased, sold, or redeemed any of its listed shares during the reporting period[76] - The board believes that the foreign exchange risk has minimal impact on the group[56] Cost Management - The distribution and selling costs as a percentage of revenue for 2023 were 44.2%, a decrease of 2.6% from 46.8% in the same period last year[52] - Administrative expenses decreased from RMB 37,153,000 for the three months ending March 31, 2022, to RMB 16,387,000 in the same period of 2023[52]

Financial Performance - The Group's revenue for 2022 was RMB 841,586,000, representing a 19.3% increase from RMB 705,456,000 in 2021[27]. - Sales of Chinese medicines and pharmaceutical products increased to RMB 841,586,000 in 2022, up from RMB 705,456,000 in 2021, representing a growth of approximately 19.3%[43]. - The profit attributable to owners of the Company for the year ended December 31, 2022, was RMB 193,565,000, up from RMB 143,283,000 in 2021, reflecting a growth of approximately 35.2%[52]. - Other income and gains for the year were approximately RMB 59,737,000, compared to RMB 51,616,000 in 2021[142]. - The gross profit margin for the year ended December 31, 2022, was approximately 77%, a decrease of 5.2% from 82.2% in 2021[142]. - Basic earnings per share rose to RMB 34.55 cents from RMB 25.57 cents, marking an increase of 35.2%[162]. Assets and Liabilities - Total assets increased to RMB 2,372,841,000 in 2022 from RMB 2,072,313,000 in 2021[142]. - The Group's total liabilities and equity as of 31 December 2022 were not disclosed in the provided documents, but the increase in assets suggests potential growth in equity[75]. - The Group's total liabilities to total assets ratio was 32% (2021: 30%) calculated from total liabilities of RMB 760,543,000 (2021: RMB 618,564,000) and total equity and liabilities of RMB 2,372,841,000 (2021: RMB 2,072,313,000)[144]. - The Group's gearing ratio, derived from total borrowings to total net assets, was 0.02% (2021: 0.03%) as of December 31, 2022[144]. Investments - As of December 31, 2022, the company held Wealth Management Products totaling approximately RMB263,074,000, with unrealized gains from fair value changes amounting to approximately RMB3,074,000[5]. - The Group's investment in time deposits as of December 31, 2022, was approximately RMB866,856,000, up from RMB806,918,000 in 2021[95]. - The Group's total initial investment cost in wealth management products was RMB 260,000,000[164]. - The fair value of unlisted financial assets increased to RMB 263,074,000 in 2022 from RMB 176,533,000 in 2021[171]. Research and Development - The Group invested approximately RMB40,440,133 in research and development projects during the year[97]. - The R&D department successfully developed the Compound Huonaoshu capsule, which significantly contributed to the Group's revenue and led to its listing in Hong Kong[97]. - The Company has enhanced its R&D capabilities by building a new R&D inspection center with advanced equipment for new product trials[142]. - The company has been actively involved in the research and development of new medicines, including three new products: Infantile spleen-strengthening oral solution, Colon Recovery Capsule, and Ginseng Glycopeptide Injection[124]. Employee and Management - The Group's contribution to retirement benefits schemes for the year ended 31 December 2022 amounted to RMB2,720,000, a significant increase from RMB597,000 in 2021, representing a growth of approximately 354%[67]. - Salaries, allowances, and other benefits increased to RMB4,479,000 in 2022 from RMB2,832,000 in 2021, reflecting a growth of about 58%[65]. - The Company has a total of 823 employees, with remuneration based on market conditions and individual performance, including discretionary bonuses and other benefits[144]. - The executive general manager, Zhang Yi, has been with the company since 2015, contributing to its strategic direction and management[122]. Inventory and Assets Management - Total inventories increased to RMB 138,880,000 in 2022 from RMB 87,168,000 in 2021, with a provision for obsolete and slow-moving inventories of RMB 5,893,000[115]. - The carrying amount of goodwill as of December 31, 2022, remained unchanged at RMB 6,254,000, with no impairment loss recognized[136]. - The carrying amount of bearer biological assets, specifically ginseng, remained stable at RMB15,080,000 for both 2022 and 2021[71]. - The company recognized a provision for obsolete and slow-moving inventories amounting to approximately RMB 5,038,000, compared to RMB 735,000 in 2021[138]. Taxation - The PRC corporate income tax for the current year was RMB 20,957,000, with a deferred taxation of RMB 26,727,000, compared to RMB 30,520,000 in 2021[34]. - Deferred income tax assets are recognized only if it is probable that future taxable profit will be available[19]. - The net deferred tax assets/(liabilities) stood at RMB 23,289,000 in 2022, compared to a net liability of RMB 2,353,000 in 2021[199]. Corporate Governance and Compliance - The Group is committed to maintaining high environmental and social standards, complying with all relevant laws and regulations related to health, safety, and the environment[144]. - The Group encourages participation in environmental and social activities that benefit the community as a whole[144]. - The Group has established a Risk Management Committee to enhance the assessment and management of investments in Wealth Management Products and time deposits[95].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全 部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 二 零 二 二 年 度 業 績 公 告 吉林省輝南長龍生化藥業股份有限公司（「本公司」）之董事會（「董事會」）欣然宣 佈，本公司及其附屬公司截至二零二二年十二月三十一日止年度之經審核業 績。本公告載列本公司二零二二年年報全文，乃符合香港聯合交易所有限公司 （「聯交所」）GEM證券上市規則（「GEM上市規則」）有關年度業績初步公告附載之 資料之相關規定。 承董事會命 吉林省輝南長龍生化藥業股份有限公司 主席 張弘 中國吉林省 二零二三年三月三十一日 ...

Financial Performance - For the nine months ended September 30, 2022, the company's revenue was RMB 593,415,000, representing a 25.3% increase from RMB 473,661,000 in the same period of 2021[4] - Gross profit for the nine months ended September 30, 2022, was RMB 469,804,000, up 23.7% from RMB 379,611,000 year-on-year[4] - Operating profit for the nine months ended September 30, 2022, was RMB 123,929,000, compared to RMB 118,720,000 in the same period of 2021, reflecting a growth of 4.0%[4] - Profit attributable to equity holders for the nine months ended September 30, 2022, was RMB 104,658,000, an increase of 7.4% from RMB 96,969,000 in the previous year[4] - Basic earnings per share for the nine months ended September 30, 2022, was 18.68 cents, compared to 17.3 cents for the same period in 2021, marking an increase of 8.0%[4] - The company reported a total sales cost of RMB 123,611,000 for the nine months ended September 30, 2022, which is an increase from RMB 94,050,000 in the same period of 2021[4] - The company’s other income for the nine months ended September 30, 2022, was RMB 18,804,000, compared to RMB 13,990,000 in the same period of 2021, indicating a growth of 34.0%[4] - The company incurred tax expenses of RMB 18,577,000 for the nine months ended September 30, 2022, down from RMB 21,544,000 in the same period of 2021[8] - The company’s administrative expenses increased to RMB 90,494,000 for the nine months ended September 30, 2022, compared to RMB 60,497,000 in the same period of 2021, reflecting a rise of 49.5%[4] - The gross margin for the nine months ended September 30, 2022, was approximately 79.17%, a decrease of 0.97% from 80.14% in the previous year[13] - Selling expenses as a percentage of revenue increased to 46.2% from 45.3% in the previous year, attributed to higher advertising and promotional costs[13] Financial Position - As of September 30, 2022, the group maintained a strong financial position with cash and bank balances of approximately RMB 852,968,000 and a net asset value of approximately RMB 1,558,407,000[15] - The group had zero short-term bank borrowings as of September 30, 2022, resulting in a capital-to-debt ratio of 0%[16] Corporate Governance - The company adopted a code of conduct for securities trading by directors, ensuring compliance with GEM Listing Rules, with no known violations reported[29] - The company did not fully comply with GEM Listing Rules regarding corporate governance practices, specifically the separation of roles between the chairman and CEO, which are held by the same individual[30] - The audit committee, established in May 2001, is responsible for overseeing the financial reporting process and internal control systems, having reviewed the unaudited results for the period ending September 30, 2022[33] - No repurchase, sale, or redemption of the company's listed shares occurred during the nine-month period ending September 30, 2022[34] - The board consists of 6 executive directors and 3 independent non-executive directors as of the report date[35] Business Development - The company has completed the renovation of its biochemical extraction workshop, expected to commence production in 2022[14] - A new R&D inspection center has been established and was officially put into use in September 2021 for new product development and quality control[14] - Management believes that the Haikun Shenxi capsule has matured in the market and has replaced the compound Huonaoshush capsule as the group's best-selling product[17] - The group is committed to identifying potential business opportunities to create substantial results in the coming years[17]

Financial Performance - For the six months ended June 30, 2022, the company reported a revenue of RMB 377,295,000, representing a 25.2% increase from RMB 301,326,000 in the same period of 2021[4] - Gross profit for the same period was RMB 297,844,000, up 24.5% from RMB 239,108,000 year-on-year[4] - Operating profit increased to RMB 92,043,000, a 46.8% rise compared to RMB 62,694,000 in the previous year[4] - The net profit attributable to shareholders was RMB 77,255,000, reflecting a 57.7% increase from RMB 48,977,000 in the prior year[4] - Basic earnings per share rose to 13.79 cents, compared to 8.74 cents in the same period last year, marking a 57.5% increase[4] - The company's revenue for the six months ended June 30, 2022, was RMB 389,825,000, representing a 25.9% increase from RMB 309,297,000 in the same period of 2021[15] - The operating profit for the six months ended June 30, 2022, was RMB 77,255,000, compared to RMB 48,977,000 for the same period in 2021, marking a 57.8% increase[19] - The basic earnings per share for the six months ended June 30, 2022, was RMB 0.138, up from RMB 0.087 in the same period of 2021[19] - The company's net profit for the six months ended June 30, 2022, was RMB 77,255,000, compared to RMB 48,977,000 for the same period in 2021, indicating a 57.8% growth[19] - The gross margin for the six months ended June 30, 2022, was approximately 78.9%, a decrease of 0.5% from 79.4% for the same period in 2021[45] Assets and Liabilities - Total assets as of June 30, 2022, amounted to RMB 2,595,530,000, compared to RMB 2,072,313,000 at the end of 2021[5] - Current assets increased to RMB 1,017,610,000 from RMB 889,873,000, indicating a growth of 14.4%[5] - The company's cash and cash equivalents rose to RMB 84,671,000, up from RMB 55,294,000, representing a 53.2% increase[5] - Total liabilities increased to RMB 585,917,000 from RMB 571,794,000, showing a slight rise of 2.5%[7] - The company maintained a stable equity position with total equity reaching RMB 1,531,004,000, up from RMB 1,453,749,000, reflecting a growth of 5.3%[7] - The total assets of the company as of June 30, 2022, were RMB 1,531,004,000, an increase from RMB 1,394,459,000 as of December 31, 2021[19] - Inventory as of June 30, 2022, totaled RMB 104,541,000, up from RMB 86,313,000 as of December 31, 2021[37] - Trade receivables as of June 30, 2022, amounted to RMB 272,296,000, compared to RMB 230,252,000 as of December 31, 2021[39] Operational Developments - The company has established a new R&D inspection center equipped with advanced facilities for new product development and quality control, officially in use since September 2021[46] - The company plans to officially launch the renovated biochemical extraction workshop in 2022 to meet market demand[46] - The company aims to continue developing potential business opportunities to drive future growth[54] Shareholder Information - As of June 30, 2022, Mr. Zhang Hong holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[56] - Mr. Zhang Xiaoguang owns 42,315,000 shares, accounting for 10.91% of domestic shares and 7.55% of total registered capital[56] - Huinan County Caiyuan Investment Co., Ltd. holds 81,975,000 shares, which is 21.14% of domestic shares and 14.63% of total registered capital[60] Corporate Governance - The audit committee consists of three independent non-executive directors, ensuring oversight of the company's financial processes and internal controls[66] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM Listing Rules[63] - No arrangements were made for directors or senior management to acquire rights to benefit from purchasing the company's shares or bonds during the reporting period[57] - The company did not identify any other individuals holding interests or short positions in the company's shares outside of the disclosed parties as of June 30, 2022[61] - The chairman and CEO roles are held by the same individual, Mr. Zhang Hong, which the board believes does not affect accountability or independent decision-making[64] Employment and Share Transactions - The company employed 956 staff members as of June 30, 2022, an increase from 951 staff members a year earlier[67] - The company did not repurchase, sell, or redeem any of its listed shares during the six-month period ending June 30, 2022[68]

吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited Jilin Province Huinan Changlong Bio-pharmacy Company Limited (股份代號：8049) 第一季度業績報告2022 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不會就本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 本報告乃遵照GEM證券上市規則（「GEM上市規則」）提供有關吉林省輝南長龍生 ...

Financial Performance - The total revenue for the year ended December 31, 2021, was approximately RMB 705,456,000, representing a 13% increase compared to RMB 622,250,000 in the previous year[14]. - Profit attributable to owners of the Company increased to RMB 143,283,000 from RMB 126,558,000 last year[14]. - Basic earnings per share rose to RMB 25.57 cents from RMB 22.59 cents in the previous year[14]. - For the year ended 31 December 2021, the Group's revenue increased to RMB 705,456,000 from approximately RMB 622,250,000, representing an increase of about 13.38%[35]. - Profit for the year attributable to owners of the Company increased to RMB 143,283,000 from RMB 126,558,000, reflecting a growth of approximately 13.19%[35]. - Basic earnings per share rose to RMB 25.57 cents from RMB 22.59 cents, marking an increase of about 13.2%[35]. - Profit before income tax for 2021 was RMB 177,273,000, compared to RMB 150,041,000 in 2020, reflecting a growth of 18.2%[89]. - The audited profit attributable to owners of the Company was approximately RMB 143,283,000, representing a 13% increase from RMB 126,558,000 in the previous year[50]. Operational Challenges - The Company faced rising production costs due to stricter national quality and environmental protection standards for pharmaceuticals[15]. - The overall price level of pharmaceuticals continued to decline following the implementation of drug price control policies, increasing operational pressure on pharmaceutical enterprises[15]. - The pandemic situation in many regions of the country remained severe, affecting major sales provinces[15]. - The company faced significant operational pressures due to rising production costs and declining drug prices, yet successfully achieved its project goals for the year[16]. - The core revenue source, Hai Kun Shen Xi capsule, remained unaffected despite rising production costs and price control policies in the pharmaceutical sector[35]. Research and Development - Investment in research and development of new drugs was increased, collaborating with pharmaceutical universities and research institutes to develop technologically advanced drugs with independent intellectual property rights[20]. - The Group has focused on enhancing R&D capabilities by building a new R&D inspection center with advanced equipment[52]. - A new R&D and testing center was built and officially put into operation in September 2021, aimed at improving product development and quality control[47]. - The Group invested approximately RMB48,466,749 in research and development projects during the year[44]. Financial Management - As at 31 December 2021, the Company held Wealth Management Products totaling approximately RMB 176,533,000[37]. - The expected annualised return rate of the Wealth Management Products subscribed during the year was around 2.25%–4.13%, compared to 1.58%–3.8% in 2020[35]. - Unrealised gains on fair value change from the Wealth Management Products amounted to approximately RMB 1,533,000 as at 31 December 2021[39]. - The Group's investments in Wealth Management Products were primarily in lower-risk options issued by major banks in China[41]. - The management has shifted investment strategy towards time deposits due to decreasing expected returns on Wealth Management Products[42]. - The Group's investment in time deposits as of December 31, 2021, was approximately RMB806,918,000, slightly up from RMB805,020,000 in 2020[42]. Corporate Governance - The Company has complied with the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules throughout the year ended 31 December 2021[140]. - The Audit Committee is composed exclusively of Independent Non-Executive Directors, ensuring independent oversight[150]. - The Company has implemented adequate systems of internal controls and risk management procedures as part of its corporate governance practices[143]. - The Board meets at least four times a year to discuss business development, operations, and financial performance[145]. - The Company has made specific inquiries of all Directors regarding compliance with the required standard of dealings, with no non-compliance reported[140]. Employee and Stakeholder Engagement - The company expressed gratitude to staff and stakeholders for their support and contributions in 2021, emphasizing the importance of teamwork in achieving success[33]. - The Group has encouraged participation in environmental and social activities among employees, customers, suppliers, and other stakeholders[54]. - The Group has enhanced cooperation with suppliers to ensure the provision of high-quality products and services[54]. Future Outlook - The Company aims to leverage its competitive advantages to achieve new accomplishments in the coming years[15]. - The company is committed to exploring and adjusting its business strategy, focusing on sustainable development and increasing investment in technology and product R&D[24]. - The company aims to adapt to new challenges and achieve rapid growth by focusing on pharmaceutical quality, market sales, and scientific innovation[32].

吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited Jilin Province Huinan Changlong Bio-pharmacy Company Limited (股份代號：8049) 第三季度業績報告2021 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就因本報告全部或部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本報告（吉林省輝南長龍生化藥業股份有限公司的董事（「董事」）願 ...

Financial Performance - For the six months ended June 30, 2021, the company reported revenue of RMB 301,326,000, an increase of 5.8% compared to RMB 285,644,000 for the same period in 2020[4] - Gross profit for the same period was RMB 239,108,000, a decrease of 1.8% from RMB 243,274,000 year-on-year[4] - Operating profit increased to RMB 62,694,000, up 1.4% from RMB 61,844,000 in the previous year[4] - Profit attributable to shareholders was RMB 48,977,000, down 5.5% from RMB 51,686,000 in the same period last year[4] - Basic earnings per share for the six months was 8.74 cents, compared to 9.23 cents in the previous year[4] - The operating profit for the six months ended June 30, 2021, was RMB 48,977,000, down from RMB 51,686,000 in the same period of 2020, reflecting a decrease of approximately 5.23%[20] - The basic earnings per share for the six months ended June 30, 2021, was RMB 0.087, down from RMB 0.092 in the same period of 2020, indicating a decrease of approximately 5.43%[20] - The gross margin for the six months ended June 30, 2021, was approximately 79.4%, down 5.9% from 85.3% in the same period of 2020[45] Assets and Liabilities - Total non-current assets as of June 30, 2021, amounted to RMB 1,090,544,000, an increase from RMB 996,616,000 at the end of 2020[6] - Current assets totaled RMB 803,799,000, slightly down from RMB 807,887,000 at the end of 2020[6] - Current liabilities increased to RMB 452,222,000 from RMB 415,435,000 at the end of 2020[6] - The company's net asset value as of June 30, 2021, was RMB 1,394,459,000, up from RMB 1,345,482,000 at the end of 2020[8] - The total assets of the company as of June 30, 2021, were RMB 167,745,000, compared to RMB 169,969,000 as of December 31, 2020, showing a decrease of about 1.31%[24] Dividends - The company did not declare any dividends for the period[4] - The company did not declare an interim dividend for the six months ended June 30, 2021, consistent with the previous year[21] - The company proposed a special dividend of RMB 0.0275 per share, subject to shareholder approval[44] Tax and Expenses - The income tax expense for the six months ended June 30, 2021, was RMB 13,526,000, compared to RMB 9,481,000 in the same period of 2020, which is an increase of about 42.4%[19] - The company’s depreciation expense for the six months ended June 30, 2021, was RMB 11,441,000, compared to RMB 10,114,000 in the same period of 2020, representing an increase of approximately 13.09%[17] - Sales expenses accounted for 43% of revenue for the six months ended June 30, 2021, a decrease from 44% in the same period of 2020[45] Shareholder Information - As of June 30, 2021, Mr. Zhang Hong holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[56] - Huinan County Caiyuan Investment holds 81,975,000 shares, accounting for 21.14% of domestic shares and 14.63% of total registered capital[60] - The company did not repurchase, sell, or redeem any of its listed shares during the six-month period ending June 30, 2021[69] Corporate Governance - The audit committee consists of three independent non-executive directors, responsible for reviewing the financial procedures and internal control systems of the group[67] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM Listing Rules[64] - No directors or senior management were granted or exercised any rights to acquire benefits through the purchase of the company's shares or bonds during the period[58] - The company reported no knowledge of any other individuals holding interests or short positions in the company's shares and related securities, aside from those disclosed[61] - The company has not established any arrangements allowing directors or senior management to acquire rights in any other corporations[58] - The company believes that having an executive chairman is in the best interest of the group, as it benefits from the chairman's deep understanding of the business[65] Workforce - The company employed 951 staff members as of June 30, 2021, an increase from 856 staff members on June 30, 2020[68] Research and Development - The company plans to develop 16 new products in the areas of generic drug research and production, enhancing its R&D capabilities and market competitiveness[48] - The company upgraded production facilities to increase production capacity and meet market demand[46] Risk Management - The company believes that foreign exchange risk has minimal impact on its operations[49] - The company maintained a capital debt ratio of approximately 0% as of June 30, 2021, with no short-term bank borrowings[51]